The latest evidence on overtreatment and the appropriate use of available therapies in breast cancer will be featured in the June 7 Education Session, “Less Is More: A Multidisciplinary Conversation on Treatment Options.”
New medications and longer survival rates have helped spur new ASCO guidelines on how clinicians can best treat their patients with different subsets of breast cancer. Compiled by co-chairs who worked with panels of experts from around the world, the guidelines encompass all aspects of cancer care.
In recognition of his work focused on improving the effectiveness of endocrine therapy and understanding the mechanism of resistance to endocrine therapy in patients with breast cancer, Dr. C. Kent Osborne receives the 2016 Gianni Bonadonna Breast Cancer Award and Lecture.
Two updated guidelines on biomarkers will guide decisions about various therapies for patients with metastatic and early-stage invasive breast cancer, while a third represents initial recommendations on the use of endocrine therapy for women with hormone receptor–positive metastatic breast cancer.
Ovarian function suppression has the potential to affect fertility, however providers should be aware of the role of adjuvant therapy and other interventions in helping patients maintain bone density and reduce fracture risk.
The Triple Negative Breast Cancer Foundation was founded in 2006 with the goal of providing funds and services for researchers and patients, including symposia, CME courses, research grants, webinars, and teleconferences on the latest treatments.
In patients with previously untreated HER2-positive metastatic breast cancer, T-DM1 appears to be noninferior to trastuzumab plus a taxane but is not superior to HT, and the addition of pertuzumab to T-DM1 offers no efficacy benefit, based on results of the randomized, phase III MARIANNE trial.
One year of neratinib improved the rate of invasive disease-free survival compared to placebo in patients with HER2-positive early breast cancer who had undergone prior adjuvant therapy with chemotherapy and trastuzumab, according to results of the randomized ExteNET trial.